Short answer
Abbott Laboratories (ABT) filed an 8-K current report with the SEC on August 20, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Filing contains signature and cover-page XBRL references only.
Abbott Laboratories 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Filing contains signature and cover-page XBRL references only
- No substantive Regulation FD disclosure or investor-actionable operating information provided
Item 8.01 · Other Events
- Abbott agreed to resolve Gill and approximately 2,000 additional NEC claims for approximately $670 million
- Settlement avoids approximately $600 million Gill judgment plus accrued interest after Missouri appellate affirmation
- Agreements represent a compromise without admission of liability, preserving Abbott’s position on product safety
- Approximately 1,700 lawsuits involving roughly 12,700 infants remain pending across federal and state courts
- Settlement materially reduces litigation uncertainty but leaves substantial NEC claims and potential future costs outstanding
Item EX-99.1 · Exhibit EX-99.1
- Settlement agreements resolve Gill and claims involving approximately 2,000 individuals for approximately $670 million
- $670 million exceeds approximately $600 million needed to satisfy the Gill judgment and accrued interest
- Approximately 1,700 lawsuits remain, involving claims for approximately 12,700 infants
- Abbott avoids further Gill appeals while reducing a portion of specialty-formula litigation exposure
- Favorable 2026 court rulings support Abbott’s safety and learned-intermediary defenses, but substantial litigation uncertainty remains
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Abbott Laboratories 8-K filings
Get the next ABT 8-K as it lands
Follow ABT for push alerts, or ask the research agent what this filing means.